The most clinically consequential number coming out of ERA 2026 isn’t a p-value — it’s 2.5 years. That’s how long the ALIGN trial has now tracked eGFR in IgA nephropathy patients on atrasentan, making it one of the longer continuous efficacy windows in a disease where renal function loss historically unfolds over decades but accelerates unpredictably. Late-breaking data from ALIGN and the APPLAUSE-IgAN final readout for iptacopan will both hit the same afternoon session on June 4, creating an unusually direct opportunity to compare mechanistic approaches — endothelin receptor antagonism versus complement inhibition — across largely overlapping patient populations.
The APPLAUSE-IgAN data carries specific weight because it includes prespecified subgroup analyses examining near-normal kidney function decline, a framing that moves well beyond proteinuria reduction as a surrogate. That is a deliberate endpoint evolution. Regulators and nephrologists have increasingly pressured sponsors to demonstrate eGFR slope preservation rather than relying on urine protein-creatinine ratio as a proxy for long-term renal survival. If the subgroup data hold, iptacopan’s label positioning in IgAN strengthens considerably — not just as a complement inhibitor but as an agent with durable structural protection across identifiable patient subsets.
Zigakibart’s 124-week Phase I/II data represent a different kind of signal. Anti-APRIL therapy targets the upstream B-cell survival factor driving IgAN pathogenesis, placing it mechanistically upstream of both atrasentan and iptacopan. Two-year follow-up in a Phase I/II context is unusually extended and suggests Novartis is building a durable safety and efficacy narrative before committing to Phase III design — or, alternatively, that the data required longer maturation to tell a clean story. Either way, the 124-week horizon gives nephrologists something concrete to evaluate against shorter-duration benchmarks from competitors. The farabursen Phase III design disclosure for ADPKD, an anti-miR-17 oligonucleotide, rounds out the portfolio picture by signaling Novartis is pushing into genetically defined kidney disease beyond immune-mediated pathology.
The single marker worth tracking from June 4 is whether APPLAUSE-IgAN’s final eGFR slope data in the subgroup analyses meet the threshold that would support a labeling update framing iptacopan as a kidney-protective agent — not merely an anti-proteinuric one. That distinction drives prescribing behavior and payer tier placement more than any other variable in this therapeutic space.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
